Radiation Oncology

SABCS 2025

Questions discussed in this category

What are your top takeaways in Medical Oncology from SABCS 2025?

6 Answers available

How will the LORETTA and COMET trials influence your treatment of low-risk DCIS?

6 Answers available

What are your top takeaways in Radiation Oncology from SABCS 2025?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2025 Oct 29

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.

JAMA, 2025 Dec 12

Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.

The New England journal of medicine, 2024 Dec 11

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.

Lancet, 2024 Apr 27

3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Sep 12

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 18

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.

Future oncology (London, England), 2023 Aug 01

TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.

Cancer, 2009-04-15

Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation.

Lancet, 2022 Aug 06

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.

JAMA oncology, 2023 Sep 21

Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial.

The New England journal of medicine, 2024 Dec 12

Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014 Nov 04

Evaluation of axillary dose coverage following whole breast radiotherapy: variation with the breast volume and shape.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018 Oct 07

Mapping of the functional anatomy of lymphatic drainage to the axilla in early breast cancer: A cohort study of 933 cases.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017 Jan 04

Ipsilateral axillary recurrence after breast conservative surgery: The protective effect of whole breast radiotherapy.

JAMA, 2025 Mar 18

Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.

JAMA, 2025 Mar 18

Is It Time to Abandon Surgery for Low-Risk DCIS?

Related Topics in Radiation Oncology